[SCHEDULE 13G/A] Monopar Therapeutics Inc. SEC Filing
Janus Henderson Group plc reports a substantial disclosed holding in Monopar Therapeutics Inc. The filing shows the group beneficially owns 1,172,368 shares of Monopar common stock, representing 19.2% of the class, held with shared voting and shared dispositive power and no sole voting or dispositive power. A related vehicle, Janus Henderson Biotech Innovation Master Fund Ltd, holds 1,006,928 shares ( 16.5%). The filing states these securities are held in the ordinary course of business and were not acquired to change or influence control. The filing also includes a power of attorney authorizing named compliance officers to execute required ownership reports.
Janus Henderson Group plc comunica una partecipazione rilevante resa pubblica in Monopar Therapeutics Inc. La dichiarazione indica che il gruppo detiene beneficiariamente 1.172.368 azioni del capitale ordinario di Monopar, pari al 19,2% della classe, con potere di voto condiviso e potere dispositivo condiviso e senza potere di voto o potere dispositivo esclusivo. Un veicolo correlato, Janus Henderson Biotech Innovation Master Fund Ltd, detiene 1.006.928 azioni (16,5%). La comunicazione precisa che questi titoli sono detenuti nell'ambito ordinario dell'attivit脿 aziendale e non sono stati acquisiti per modificare o influenzare il controllo. La dichiarazione include inoltre una procura che autorizza i responsabili della conformit脿 indicati a presentare i rapporti di propriet脿 richiesti.
Janus Henderson Group plc comunica una tenencia divulgada significativa en Monopar Therapeutics Inc. El formulario indica que el grupo posee a t铆tulo beneficiario 1.172.368 acciones de las acciones ordinarias de Monopar, lo que representa el 19,2% de la clase, con poder de voto compartido y facultad dispositiva compartida y sin facultad dispositiva ni de voto exclusiva. Un veh铆culo relacionado, Janus Henderson Biotech Innovation Master Fund Ltd, posee 1.006.928 acciones (16,5%). El documento se帽ala que estos valores se mantienen en el curso ordinario del negocio y no se adquirieron para cambiar o influir en el control. El informe tambi茅n incluye un poder que autoriza a los responsables de cumplimiento nombrados a presentar los informes de propiedad requeridos.
Janus Henderson Group plc电� Monopar Therapeutics Inc.鞐� 雽�頃� 欷戩殧頃� 瓿奠嫓 歆�攵勳潉 氤搓碃頄堨姷雼堧嫟. 鞝滌稖 靹滊鞐� 霐半ゴ氅� 攴鸽９鞚� Monopar 氤错喌欤� 1,172,368欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅� 鞚吹鐢 頃措嫻 霌标笁鞚� 19.2%鞐� 頃措嫻頃橁碃, 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓�鞙茧 氤挫湢霅橃柎 雼弲 鞚橁舶甓岇澊雮� 雼弲 觳橂秳甓岇潃 鞐嗠嫟瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 甏�霠� 旮瓣磤鞚� Janus Henderson Biotech Innovation Master Fund Ltd电� 1,006,928欤�(16.5%)毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 靹滊鞐惖鐢 鞚� 歃濌秾霌れ澊 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 氤挫湢霅� 瓴冹澊氅� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲媹霛嫉鐢 雮挫毄鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 氇呾嫓霅� 欷�氩曣皭鞁� 雼措嫻鞛愲摛鞚� 頃勳垬 靻岇湢 氤搓碃靹滊ゼ 鞝滌稖頃� 靾� 鞛堧弰搿� 頃樀鐢 鞙勳瀯鞛ル弰 韽暔霅橃柎 鞛堨姷雼堧嫟.
Janus Henderson Group plc d茅clare une participation importante port茅e 脿 connaissance dans Monopar Therapeutics Inc. Le d茅p么t indique que le groupe d茅tient 脿 titre b茅n茅ficiaire 1 172 368 actions d'actions ordinaires de Monopar, repr茅sentant 19,2 % de la cat茅gorie, d茅tenues avec pouvoir de vote partag茅 et pouvoir dispositif partag茅, et sans pouvoir de vote ni pouvoir dispositif exclusif. Un v茅hicule li茅, Janus Henderson Biotech Innovation Master Fund Ltd, d茅tient 1 006 928 actions (16,5 %). Le d茅p么t pr茅cise que ces titres sont d茅tenus dans le cadre normal des activit茅s et n'ont pas 茅t茅 acquis dans le but de modifier ou d'influencer le contr么le. Le dossier inclut 茅galement une procuration autorisant les responsables conformit茅 nomm茅s 脿 remplir les d茅clarations de d茅tention requises.
Janus Henderson Group plc meldet eine wesentliche offenlegungspflichtige Beteiligung an Monopar Therapeutics Inc. Die Einreichung weist aus, dass die Gruppe wirtschaftlich 1.172.368 Aktien der Stammaktien von Monopar h盲lt, was 19,2% der Klasse entspricht, und diese mit gemeinsamen Stimmrechten und gemeinsamer Verf眉gungsbefugnis gehalten werden, ohne alleinige Stimm- oder Verf眉gungsbefugnis. Ein verbundenes Vehikel, Janus Henderson Biotech Innovation Master Fund Ltd, h盲lt 1.006.928 Aktien (16,5%). In der Meldung hei脽t es, dass diese Wertpapiere im gew枚hnlichen Gesch盲ftsbetrieb gehalten werden und nicht erworben wurden, um die Kontrolle zu 盲ndern oder zu beeinflussen. Die Einreichung enth盲lt au脽erdem eine Vollmacht, die benannte Compliance-Beauftragte bevollm盲chtigt, die erforderlichen Eigentumsberichte zu unterzeichnen.
- Material disclosure of 19.2% ownership (1,172,368 shares) by Janus Henderson Group plc
- Related fund holds 16.5% (1,006,928 shares), showing substantial investor interest
- Holdings reported with shared voting and dispositive power, not sole control
- Filing states securities were acquired and are held in the ordinary course, not to change control
- Power of attorney included to authorize compliance officers to make required filings
- None.
Insights
TL;DR Janus Henderson disclosed a material 19.2% stake in MNPR, a significant ownership position disclosed on Schedule 13G/A.
The holding of 1,172,368 shares (19.2%) is large relative to the public float and qualifies as a material position that must be disclosed. The report clarifies the position is held in the ordinary course of business and not for the purpose of changing control, and the group reports shared voting and dispositive powers rather than sole control. For investors, this confirms concentrated institutional interest but does not, per the filing, indicate an active campaign to influence governance.
TL;DR A near-20% beneficial ownership with shared voting power is material and could translate to governance influence, though the filer disclaims control intent.
The disclosure shows Janus Henderson Group plc and a related fund together occupy large stakes (19.2% and 16.5% individually). The filing records shared voting and dispositive power and an explicit certification that the securities are not held to effect control changes. The inclusion of a power of attorney for compliance officers to file reports is standard governance practice for group filings and ensures timely regulatory compliance.
Janus Henderson Group plc comunica una partecipazione rilevante resa pubblica in Monopar Therapeutics Inc. La dichiarazione indica che il gruppo detiene beneficiariamente 1.172.368 azioni del capitale ordinario di Monopar, pari al 19,2% della classe, con potere di voto condiviso e potere dispositivo condiviso e senza potere di voto o potere dispositivo esclusivo. Un veicolo correlato, Janus Henderson Biotech Innovation Master Fund Ltd, detiene 1.006.928 azioni (16,5%). La comunicazione precisa che questi titoli sono detenuti nell'ambito ordinario dell'attivit脿 aziendale e non sono stati acquisiti per modificare o influenzare il controllo. La dichiarazione include inoltre una procura che autorizza i responsabili della conformit脿 indicati a presentare i rapporti di propriet脿 richiesti.
Janus Henderson Group plc comunica una tenencia divulgada significativa en Monopar Therapeutics Inc. El formulario indica que el grupo posee a t铆tulo beneficiario 1.172.368 acciones de las acciones ordinarias de Monopar, lo que representa el 19,2% de la clase, con poder de voto compartido y facultad dispositiva compartida y sin facultad dispositiva ni de voto exclusiva. Un veh铆culo relacionado, Janus Henderson Biotech Innovation Master Fund Ltd, posee 1.006.928 acciones (16,5%). El documento se帽ala que estos valores se mantienen en el curso ordinario del negocio y no se adquirieron para cambiar o influir en el control. El informe tambi茅n incluye un poder que autoriza a los responsables de cumplimiento nombrados a presentar los informes de propiedad requeridos.
Janus Henderson Group plc电� Monopar Therapeutics Inc.鞐� 雽�頃� 欷戩殧頃� 瓿奠嫓 歆�攵勳潉 氤搓碃頄堨姷雼堧嫟. 鞝滌稖 靹滊鞐� 霐半ゴ氅� 攴鸽９鞚� Monopar 氤错喌欤� 1,172,368欤�毳� 鞁れ鞝侅溂搿� 氤挫湢頃橁碃 鞛堨溂氅� 鞚吹鐢 頃措嫻 霌标笁鞚� 19.2%鞐� 頃措嫻頃橁碃, 瓿惦彊 鞚橁舶甓� 氚� 瓿惦彊 觳橂秳甓�鞙茧 氤挫湢霅橃柎 雼弲 鞚橁舶甓岇澊雮� 雼弲 觳橂秳甓岇潃 鞐嗠嫟瓿� 旮办灛霅橃柎 鞛堨姷雼堧嫟. 甏�霠� 旮瓣磤鞚� Janus Henderson Biotech Innovation Master Fund Ltd电� 1,006,928欤�(16.5%)毳� 氤挫湢頃橁碃 鞛堨姷雼堧嫟. 靹滊鞐惖鐢 鞚� 歃濌秾霌れ澊 韱奠儊鞝侅澑 鞓侅梾 瓿检爼鞐愳劀 氤挫湢霅� 瓴冹澊氅� 歆�氚瓣秾鞚� 氤�瓴巾晿瓯半倶 鞓來枼霠レ潉 頄夓偓頃橁赴 鞙勴暣 旆摑霅� 瓴冹澊 鞎勲媹霛嫉鐢 雮挫毄鞚� 韽暔霅橃柎 鞛堨姷雼堧嫟. 霕愴暅 氇呾嫓霅� 欷�氩曣皭鞁� 雼措嫻鞛愲摛鞚� 頃勳垬 靻岇湢 氤搓碃靹滊ゼ 鞝滌稖頃� 靾� 鞛堧弰搿� 頃樀鐢 鞙勳瀯鞛ル弰 韽暔霅橃柎 鞛堨姷雼堧嫟.
Janus Henderson Group plc d茅clare une participation importante port茅e 脿 connaissance dans Monopar Therapeutics Inc. Le d茅p么t indique que le groupe d茅tient 脿 titre b茅n茅ficiaire 1 172 368 actions d'actions ordinaires de Monopar, repr茅sentant 19,2 % de la cat茅gorie, d茅tenues avec pouvoir de vote partag茅 et pouvoir dispositif partag茅, et sans pouvoir de vote ni pouvoir dispositif exclusif. Un v茅hicule li茅, Janus Henderson Biotech Innovation Master Fund Ltd, d茅tient 1 006 928 actions (16,5 %). Le d茅p么t pr茅cise que ces titres sont d茅tenus dans le cadre normal des activit茅s et n'ont pas 茅t茅 acquis dans le but de modifier ou d'influencer le contr么le. Le dossier inclut 茅galement une procuration autorisant les responsables conformit茅 nomm茅s 脿 remplir les d茅clarations de d茅tention requises.
Janus Henderson Group plc meldet eine wesentliche offenlegungspflichtige Beteiligung an Monopar Therapeutics Inc. Die Einreichung weist aus, dass die Gruppe wirtschaftlich 1.172.368 Aktien der Stammaktien von Monopar h盲lt, was 19,2% der Klasse entspricht, und diese mit gemeinsamen Stimmrechten und gemeinsamer Verf眉gungsbefugnis gehalten werden, ohne alleinige Stimm- oder Verf眉gungsbefugnis. Ein verbundenes Vehikel, Janus Henderson Biotech Innovation Master Fund Ltd, h盲lt 1.006.928 Aktien (16,5%). In der Meldung hei脽t es, dass diese Wertpapiere im gew枚hnlichen Gesch盲ftsbetrieb gehalten werden und nicht erworben wurden, um die Kontrolle zu 盲ndern oder zu beeinflussen. Die Einreichung enth盲lt au脽erdem eine Vollmacht, die benannte Compliance-Beauftragte bevollm盲chtigt, die erforderlichen Eigentumsberichte zu unterzeichnen.
FAQ
Who filed this Schedule 13G/A for MNPR?
How many Monopar (MNPR) shares does Janus Henderson Group plc report owning?
How many shares does Janus Henderson Biotech Innovation Master Fund Ltd report?
Does the filing state the intent behind the holdings in MNPR?
Who signed the filing on behalf of the reporting persons?
